Mineralys Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGMineralys Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 66), indicating performance broadly in line with the market. Earnings growth of 41% provides fundamental context to the price action. Investors should exercise caution due to high volatility (105% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $28.35 | +6.24% | ABOVE |
| 50 SMA | $27.20 | +10.74% | ABOVE |
| 100 SMA | $30.08 | +0.15% | ABOVE |
| 150 SMA | $33.73 | -10.71% | BELOW |
| 200 SMA | $31.22 | -3.54% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MLYS in an uptrend right now?
MLYS has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is MLYS overbought or oversold?
MLYS's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is MLYS outperforming the market?
MLYS has a Relative Strength (RS) Rating of 66 out of 99. MLYS is performing about average compared to the market.
Where is MLYS in its 52-week range?
MLYS is trading at $30.12, which is 63% of its 52-week high ($47.65) and 50% above its 52-week low ($12.59).
How volatile is MLYS?
MLYS has a Beta of 0.77 and 52-week volatility of 105%. It's less volatile than the S&P 500 - generally more stable.